Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aerie Pharmaceuticals
(NQ:
AERI
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 18, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aerie Pharmaceuticals
< Previous
1
2
Next >
Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
October 28, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
October 21, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
October 12, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
October 07, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
October 06, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 27, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
September 21, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
September 20, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
September 15, 2021
From
Aerie Pharmaceuticals
Via
Business Wire
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
September 13, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
September 07, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, Manufacturing
September 07, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
August 12, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 04, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
July 28, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
July 20, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
July 15, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training
June 21, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE
June 21, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan
June 17, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference
June 15, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference
May 06, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 05, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
April 29, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
April 28, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 28, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
April 19, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021
From
Aerie Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.